ERBB2 and breast cancer: Neoadjuvant treatment is regarded as standard-of-care for the majority of patients with early stage HER2-positive BC; with high pathologic complete remission (pCR) rates observed, several studies have concentrated on strategies of chemotherapy de-escalation.